Researchers analyzed data from the FAERS to determine the prevalence of interstitial lung disease among patients with cancer receiving antibody-drug conjugates ...
Researchers have found that patients with interstitial lung disease (ILD) are at greatly heightened risk of developing all ...
ERS/EULAR guidelines outline best practices for diagnosis, monitoring, and treatment of connective tissue disease-related ILD ...
Liquidia Corporation (NASDAQ:LQDA) is one of the Best Performing Long Term Stocks According to Analysts. On September 3, ...
Better diagnostics and more treatment options have modestly improved interstitial lung disease management in patients with ...
Machine learning model accurately diagnoses interstitial pneumonia, matching pulmonologist expertise and predicting mortality ...
Gossamer Bio, Inc. (NASDAQ:GOSS) is a late-stage clinical biopharmaceutical company focused on developing and commercializing ...
EULAR - The European Alliance of Associations for Rheumatology - has worked with the European Respiratory Society (ERS) to develop new clinical practice guidelines for interstitial lung disease (ILD) ...
Tyr Pharma ( NASDAQ: ATYR) stock fell after its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a ...
Antifibrotic drugs like pirfenidone (Esbriet; Genentech) and nintedanib (Ofev; Boehringer Ingelheim) have been shown to be effective in patients with idiopathic pulmonary fibrosis (IPF) and in some ...
Orphan drug designation from Japan’s Ministry of Health, Labour and Welfare provides key regulatory benefits, including ...
Rinatabart sesutecan is an investigational folate receptor alpha-directed, topoisomerase I inhibitor antibody-drug conjugate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback